Welcome to our dedicated page for Cardiff Oncology SEC filings (Ticker: CRDF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cardiff Oncology, Inc. (Nasdaq: CRDF) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company focused on PLK1 inhibition and its lead asset onvansertib, Cardiff Oncology uses filings such as Forms 10-K, 10-Q and 8-K to report its financial condition, clinical development progress and material corporate events.
In recent Form 8-K filings, Cardiff Oncology has furnished press releases covering quarterly financial results, business updates and positive data from the randomized Phase 2 CRDF-004 trial in first-line RAS-mutated metastatic colorectal cancer. These filings also reference presentation materials for clinical data updates and summarize key milestones in the onvansertib program. Other 8-Ks document outcomes of the annual meeting of stockholders, including director elections, auditor ratification, equity plan amendments and advisory votes on executive compensation.
Through its periodic reports, such as Form 10-K and Form 10-Q, Cardiff Oncology discusses research and development expenses, royalty revenues, cash and investment balances, and risk factors associated with clinical-stage oncology drug development. These documents outline the company’s dependence on successful clinical trials, regulatory approvals and access to capital, as well as competitive and operational risks.
On Stock Titan, each filing is accompanied by AI-powered summaries that highlight the most important points, helping readers quickly understand complex financial tables, clinical program descriptions and legal language. Users can follow new filings in near real time as they are posted to EDGAR and use this page to review Cardiff Oncology’s historical regulatory record, including information relevant to governance, compensation, capital structure and the progress of onvansertib across multiple cancer indications.
Cardiff Oncology (CRDF) filed an 8-K stating it issued a press release announcing company highlights and financial results for the third quarter ended September 30, 2025. The press release was furnished as Exhibit 99.1.
The company’s common stock trades on The Nasdaq Stock Market under the symbol CRDF. The report was signed by Chief Executive Officer Mark Erlander on November 6, 2025.
Cardiff Oncology (CRDF) reported Q3 2025 results with royalty revenue of
Cash, cash equivalents and short-term investments totaled
In its lead mCRC program, Phase 2 CRDF-004 showed blinded independent central review ORR as of July 8, 2025: control 30%, onvansertib 20mg + SoC 42%, and onvansertib 30mg + SoC 49%. The combination was described as well-tolerated. Shares outstanding were 67,360,564 as of October 30, 2025.
Cardiff Oncology, Inc. (CRDF) received a joint Schedule 13G/A from Commodore Capital LP and Commodore Capital Master LP reporting zero beneficial ownership of the issuer's common stock (CUSIP 14147L108). The filing lists each filers jurisdiction (Delaware and Cayman Islands), business addresses, and certifies the securities were not acquired to influence control of the company. The cover pages show 0.00 shares and 0.0% of the class for both filers. The document includes a signed joint filing agreement and certifications by Michael Kramarz as Managing Partner and Authorized Signatory.
Cardiff Oncology, Inc. (CRDF) – Form 4 filing dated 06/30/2025
The filing discloses that director Rodney S. Markin received 40,565 stock options on 06/26/2025 at an exercise price of $3.16 per share. The options become exercisable on 06/26/2026 and expire on 06/26/2035. The transaction is coded “A,” indicating an award or grant with no cash paid by the insider. Following the grant, Markin holds 222,865 derivative securities (stock options) directly. No open-market purchases or sales of common stock were reported, and no changes were recorded in Markin’s non-derivative share ownership.
The grant is a routine equity incentive intended to align the director’s interests with those of shareholders. Given the modest size relative to Cardiff Oncology’s total shares outstanding, the transaction is considered immaterial from a dilution standpoint and does not, by itself, signal any change to the company’s strategic outlook or financial condition.
FAQ
What is the current stock price of Cardiff Oncology (CRDF)?
What is the market cap of Cardiff Oncology (CRDF)?
